HORIZON THERAPEUTICS

HZNP
Delayed Quote. Delayed  - 09/27 04:00:00 pm
109.96USD -0.37%
Business Summary
Healthcare
Pharmaceuticals & Medical Research
 Pharmaceuticals
  Pharmaceuticals
   Other Pharmaceuticals
Horizon Therapeutics plc is a biotechnology company that is focused on researching, developing and commercializing medicines that address critical needs for people impacted by rare, autoimmune and serious inflammatory diseases. The Company's portfolio is composed of approximately 12 medicines in the areas of rare diseases, gout, ophthalmology and inflammation. The Company has two reportable segments: the orphan and the inflammation segment. The orphan segment includes the medicines TEPEZZA, KRYSTEXXA, RAVICTI, PROCYSBI, ACTIMMUNE, BUPHENYL, QUINSAIR, UPLIZNA and also the Company’s research and development (R&D) programs. TEPEZZA is a monoclonal antibody and a targeted inhibitor of the insulin-like growth factor-1 receptor (IGF-1R). KRYSTEXXA is an infused medicine for uncontrolled gout. The Company's other orphan segment medicines, RAVICTI, PROCYSBI and ACTIMMUNE, treats serious chronic diseases. The inflammation segment includes PENNSAID 2%, DUEXIS, RAYOS and VIMOVO medicines.

Number of employees : 1 395 people.
Sales per Business
20192020
Orphan929.6071.5%1 787.6681.2%
Inflammation370.4328.5%412.7718.8%
USD in Million
Sales per region
20192020
United States1 292.4299.4%2 191.1199.6%
Rest of World7.610.6%9.320.4%
USD in Million
Managers
Name Title
Timothy P. Walbert Chairman, President & Chief Executive Officer
Paul W. Hoelscher Chief Financial Officer & Executive Vice President
Jeffrey W. Sherman Chief Medical Officer & Executive Vice President
Jeffrey D. Kent Executive VP-Medical Affairs & Outcomes Research
Karin Rosen Chief Scientific Officer
Elizabeth H.Z. Thompson Executive Vice President-Research & Development
Barry J. Moze Chief Administrative Officer & Executive VP
Jeff Himawan Independent Director
William Francis Daniel Independent Director
Pascale Witz Independent Director
Shareholders
Name Equities %
The Vanguard Group, Inc. 19,442,986 8.61%
Fidelity Management & Research Co. LLC 14,522,986 6.43%
Lone Pine Capital LLC 13,997,232 6.20%
Avoro Capital Advisor LLC 9,000,000 3.98%
Paulson & Co., Inc. 7,991,440 3.54%
Consonance Capital Management LP 6,218,903 2.75%
Janus Capital Management LLC 5,824,194 2.58%
Essex Woodlands Management, Inc. 5,815,940 2.57%
SSgA Funds Management, Inc. 5,450,915 2.41%
BlackRock Fund Advisors 5,088,312 2.25%
Company contact information
Horizon Therapeutics Plc
Connaught House
1 Burlington Road
1st Floor
Dublin 4

Phone : +353.1.772.2100
Web : http://www.horizontherapeutics.com
Sector Other Pharmaceuticals
1st jan.Capi. (M$)
HORIZON THERAPEUTICS PUBLIC LIMITED COMPANY50.32%24 932
JOHNSON & JOHNSON3.68%432 675
ROCHE HOLDING AG10.16%321 605
PFIZER, INC.18.36%246 358
NOVO NORDISK A/S50.45%231 485
ELI LILLY AND COMPANY34.09%210 037
ABBVIE INC.0.53%189 211
ASTRAZENECA PLC16.97%187 304
MERCK & CO., INC.-10.32%186 334
NOVARTIS AG-8.36%186 020
BRISTOL-MYERS SQUIBB COMPANY-3.53%133 838
AMGEN INC.-7.31%121 299
SANOFI4.35%120 553
GLAXOSMITHKLINE PLC3.37%94 962
CHUGAI PHARMACEUTICAL CO., LTD.-23.17%63 921
ALLERGAN PLC0.97%63 659
TAKEDA PHARMACEUTICAL COMPANY LIMITED0.43%53 563
BAYER AG-1.79%53 487
DAIICHI SANKYO COMPANY, LIMITED-12.76%53 247
JIANGSU HENGRUI MEDICINE CO., LTD.-45.36%49 081
ASTELLAS PHARMA INC.17.63%31 844
Brand Portfolio
HORIZON THERAPEUTICS
HORIZON THERAPEUTICS
VIELA BIO
VIELA BIO
» More brands of Horizon Therapeutics Public Limited Company